Viscosupplementation Market to Surpass US$ 13.6 Billion by 2032 Amid Rising Demand for Osteoarthritis Treatment - Persistence Market Research

Overview of the Viscosupplementation Market

The global viscosupplementation market has emerged as a significant segment in the orthopedic care industry, primarily driven by the rising prevalence of osteoarthritis and the growing elderly population. In 2021, global sales reached US$ 4.4 billion, and by 2022, the market had grown to US$ 4.9 billion. It is projected to reach an impressive US$ 13.6 billion by 2032, expanding at a robust CAGR of 10.8% from 2022 to 2032. Viscosupplementation, a non-surgical treatment involving the injection of hyaluronic acid into joints, particularly the knee, has gained traction due to its ability to relieve pain and improve joint function in osteoarthritis patients.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/33245

The key growth drivers of this market include the increasing preference for non-invasive treatments, growing awareness of the benefits of hyaluronic acid therapies, and expanded FDA approvals for viscosupplement products. Among the product types, single-injection formulations dominate the market due to their ease of use, reduced pain, and minimized hospital visits. Regionally, the Asia-Pacific region leads with over 45% revenue share in 2020, fueled by a rising geriatric population, increasing cases of osteoarthritis, and a growing focus on orthopedic care in countries like China and India.

✦ Key Highlights from the Report

✦ The global market was valued at US$ 4.9 billion in 2022 and is projected to reach US$ 13.6 billion by 2032.
✦ The market is growing at a CAGR of 10.8% between 2022 and 2032.
✦ Single-injection products are anticipated to generate the highest absolute dollar opportunity of US$ 8.8 billion by 2032.
✦ Asia-Pacific is the leading region, accounting for the largest share due to its aging population and rising osteoarthritis prevalence.
✦ The U.S. market is projected to reach US$ 4.3 billion by 2032 with an 11.3% CAGR.
✦ Orthopedic clinics and ambulatory surgical centers account for over 60% of market revenues.

Market Segmentation

The viscosupplementation market is segmented based on product type, end-user, and treatment site. In terms of product type, the market is categorized into single-injection, three-injection, and five-injection formulations. Of these, single-injection viscosupplements are gaining the highest traction due to their shorter treatment schedule, reduced side effects, and enhanced patient convenience. Products such as MONOVISC by Anika Therapeutics and TriVisc by OrthogenRx exemplify this trend.

On the basis of end-user, the market includes orthopedic clinics, ambulatory surgical centers (ASCs), and hospitals. Orthopedic clinics and ASCs dominate the landscape, accounting for more than 60% of the global market share. These facilities are preferred for their specialization in musculoskeletal disorders and ability to offer outpatient care for procedures like viscosupplementation. In contrast, hospitals remain essential in regions lacking advanced orthopedic infrastructure.

Regional Insights

Regionally, Asia-Pacific stands out as the most promising market, expected to register the highest CAGR during 2022-2032. Factors such as a rising aging population, greater healthcare investments, and improved diagnostic facilities in countries like India, China, and Japan are bolstering regional growth. Notably, Japan is projected to reach US$ 1.3 billion by 2032, expanding at a CAGR of 14.1%, driven by government initiatives and innovative healthcare reforms.

The United States continues to be a dominant player in the global viscosupplementation landscape. With a projected value of US$ 4.3 billion by 2032, the U.S. market is growing at an 11.3% CAGR. Its growth is fueled by a higher prevalence of osteoarthritis, willingness to adopt premium treatment regimens, and favorable reimbursement policies. The U.K. and South Korea are also emerging as significant contributors, with respective CAGR values of 12.3% and 9.8%, supported by increasing healthcare spending and robust clinical trial activities.

Market Drivers

The key drivers of the viscosupplementation market include the increasing burden of osteoarthritis, which affects millions globally, particularly those aged 60 and above. According to the World Health Organization, the global population aged 65 and above is projected to increase from 7% in 2000 to 16% by 2050, amplifying demand for joint pain therapies. Another major factor is the shift toward non-invasive and outpatient procedures, making viscosupplementation a preferred alternative to surgical joint replacement. The clinical effectiveness of hyaluronic acid-based treatments and the availability of FDA-approved products, such as Orthovisc and Synvisc, further boost market adoption.

Market Restraints

Despite promising growth, the market faces several challenges. High treatment costs, particularly in developed countries, can limit accessibility for patients without comprehensive insurance coverage. Additionally, mixed clinical outcomes have been reported in some studies, leading to skepticism among certain medical professionals. Stringent regulatory requirements and product approval delays also pose hurdles to new entrants. Furthermore, low awareness levels in rural and developing areas hinder market penetration, especially where access to orthopedic care is limited.

Market Opportunities

The viscosupplementation market presents substantial opportunities for innovation and expansion. The increasing emphasis on personalized medicine and targeted therapies is opening new avenues for R&D in hyaluronic acid formulations. Furthermore, the expansion of reimbursement policies in countries like France and the U.S. enhances affordability and access. The development of next-generation products, such as Anika's Hyalofast, and the integration of regenerative medicine with viscosupplementation, represent exciting growth prospects. Markets in Latin America, Southeast Asia, and the Middle East remain largely untapped, offering lucrative opportunities for key players to expand their geographic footprint.

# Frequently Asked Questions (FAQs)

How big is the viscosupplementation market in 2022?
Who are the key players in the global viscosupplementation market?
What is the projected growth rate of the viscosupplementation market?
What is the market forecast for viscosupplementation through 2032?
Which region is estimated to dominate the viscosupplementation industry through the forecast period?

Company Insights

• Sanofi
• Anika Therapeutics, Inc.
• Seikagaku Corp.
• Zimmer Biomet
• Smith & Nephew PLC
• Ferring Pharmaceuticals B.V.
• Lifecore Biomedical
• LG Life Sciences Ltd.
• Fidia Farmaceutici S.p.A
• F. Hoffmann-La Roche Ltd.

Recent Developments:

In June 2019, Anika Therapeutics, Inc. introduced Hyalofast, a next-gen hyaluronic acid-based cartilage repair scaffold, at the ICRS.

In April 2018, Bone Therapeutics S.A. successfully completed clinical trials for its JTA-004 intra-articular injection, a novel treatment for knee osteoarthritis.

Conclusion

The viscosupplementation market is poised for strong growth through 2032, driven by a confluence of demographic shifts, technological advancements, and a rising preference for non-invasive treatments. With a CAGR of 10.8%, the market is expected to nearly triple in value, reflecting increasing demand for effective osteoarthritis solutions across aging populations worldwide. Product innovation, expanded reimbursement structures, and geographic diversification will be key to unlocking the next phase of market expansion. For stakeholders across the healthcare and pharmaceutical sectors, viscosupplementation represents a resilient, high-potential investment opportunity in the decade ahead.

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.